Representative EV cargoes implicated in the relationship between insulin resistance and MASLD, with the experimental design underlying each claim.
| EV cargo | Principal source | Proposed target or pathway | Reported effect | Design and strength of inference |
|---|---|---|---|---|
| miR-155 | Adipose tissue macrophages | Repression of PPAR-gamma | Glucose intolerance and insulin resistance in lean recipients; reversed with lean-donor vesicles | Adoptive transfer, genetic deletion, marrow reconstitution, GW4869; strongest causal design in the field, murine only [43] |
| miR-122, miR-192, miR-27a/b | Adipose tissue and liver | PPAR-alpha (Ppara) in white adipose tissue | Glucose intolerance, dyslipidaemia, adipose inflammation, hepatic steatosis after mimic-loaded transfer | Loaded-vesicle transfer with pharmacological rescue; causal within model, supraphysiological dosing [41] |
| Adipokine-bearing EVs (IL-6, MIF, MCP-1) | Human adipose explants | Insulin-induced AKT phosphorylation | Reduced hepatic insulin signalling; response heterogeneous, a minority of donors showing the opposite effect | Ex vivo human explant vesicles on cell lines; associative, no in vivo endpoint [40] |
| let-7e-5p | Hepatocytes (Ggpps/Rab27A-dependent) | Adipocyte lipogenic programme | Increased adipocyte lipid accumulation; plasma levels track BMI and hepatic triglyceride | Murine interventional plus human cross-sectional correlation [47] |
| TLR4 ligands | Lipotoxic hepatocytes | Islet macrophage TLR4 | Islet inflammation, impaired insulin secretion | Murine, with genetic and pharmacological TLR4 dependence demonstrated [48] |
| Ceramide and sphingosine-1-phosphate | Palmitate-stressed hepatocytes | S1P receptor 1 on macrophages | Macrophage chemotaxis; cargo depletion abrogates the effect | Knockout hepatocytes, chemotaxis assay, human plasma correlation [37, 49] |
| TRAIL | Lipotoxic hepatocytes (DR5/ROCK1) | Macrophage death receptor 5 | IL-1-beta and IL-6 induction; ROCK1 inhibition reduced vesicle release, injury and fibrosis in vivo | In vitro pathway inactivation plus in vivo pharmacological intervention [50] |
| CXCL10 | Lipotoxic hepatocytes (MLK3) | Macrophage CXCR3 | Innate immune chemotaxis; macrophage-associated inflammation in murine MASH | Genetic and pharmacological MLK3 inhibition; CXCL10-deficient models [51, 52] |
| miR-192-5p; miR-9-5p | Lipotoxic hepatocytes | Rictor/AKT/FoxO1 | M1 polarisation; serum miR-192-5p correlates with inflammatory activity | Murine mechanism plus human serum correlation [53, 54] |
| miR-128-3p | Fat-laden hepatocytes | Stellate cell PPAR-gamma | Stellate activation, proliferation, chemotaxis; upregulated collagen I, alpha-SMA, TIMP-2 | Loss- and gain-of-function in cultured stellate cells; in vitro only [55, 56] |
BMI: body mass index; CXCL10: C-X-C motif chemokine ligand 10; CXCR3: C-X-C motif chemokine receptor 3; DR5: death receptor 5; FoxO1: forkhead box protein O1; Ggpps: geranylgeranyl diphosphate synthase; IL-6: interleukin-6; MCP-1: monocyte chemoattractant protein-1; MIF: macrophage migration inhibitory factor; MLK3: mixed lineage kinase 3; Rab27A: Ras-related protein Rab-27A; ROCK1: Rho-associated coiled-coil-containing protein kinase 1; S1P: sphingosine-1-phosphate; TIMP-2: tissue inhibitor of metalloproteinases 2; TLR4: Toll-like receptor 4; TRAIL: tumour necrosis factor-related apoptosis-inducing ligand.